Effect of estrogen and 1alpha,25(OH)2- vitamin D3 on the activity and growth of human primary osteoblast-like cells in vitro.
OBJECTIVE
To evaluate effects of 17beta-E(2) and 1alpha,25(OH)(2)-vitamin D(3) on human osteoblast-like (hOB) cells.


METHODS
Controlled, experimental study.


METHODS
University hospital.


METHODS
hOB cell cultures were prepared from the upper femur of postmenopausal patients undergoing bipolar endoprosthesis arthroplasty for a fractured femoral neck.


METHODS
hOB cells were subcultured with either 17beta-E(2) or 1alpha,25(OH)(2)-vitamin D(3), or both.


METHODS
Cell proliferation and activity of alkaline phosphatase, osteocalcin, and interleukin-6.


RESULTS
17beta-E(2) significantly reduced interleukin-6 and osteocalcin to 34% and 60% of control value but induced alkaline phosphatase and cell proliferation to 183% and 150% of control value. 1alpha,25(OH)(2)-vitamin D(3) significantly decreased cell proliferation to 88% of that of control group, but 1alpha,25(OH)(2)-vitamin D(3) plus 17beta-E(2) showed no difference from the control group. Alkaline phosphatase and osteocalcin were significantly increased by 1alpha,25(OH)(2)-vitamin D(3) alone or combined with 17beta-E(2), to 169% and 198% and to 144% and 144% of control value, respectively. 1alpha,25(OH)(2)-vitamin D(3), with or without 17beta-E(2), decreased interleukin-6 levels to 27% and 38% of control group, respectively.


CONCLUSIONS
17beta-E(2) and 1alpha,25(OH)(2)-vitamin D(3) have effects on osteoblasts. The prevention of osteoporosis by estrogen may be related not only to direct effects on osteoblastic activity and proliferation but also to indirect effects on osteoclasts by the decrease of interleukin-6 secretion.
Chen
Fang-Ping
FP
Department of Obstetrics and Gynecology, Keelung Chang Gung Memorial Hospital, Republic of, Keelung, Taiwan, Republic of China.
Lee
Ning
N
Wang
Kun-Chuang
KC
Soong
Yung-Kui
YK
Huang
Ko-En
KE
D000469:Alkaline Phosphatase / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004338:Drug Combinations; D004958:Estradiol / Q000494:pharmacology*; D006801:Humans; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D015675:Osteocalcin / Q000037:antagonists & inhibitors; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000093242:Interleukin-6 Inhibitors
D000469:Alkaline Phosphatase; D004338:Drug Combinations; D004958:Estradiol; D015675:Osteocalcin; D014807:Vitamin D; D000093242:Interleukin-6 Inhibitors; C116441:2-methyl-1,25-dihydroxyvitamin D3